An alternative splicing variant of mineralocorticoid receptor discovered in preeclampsia tissues and its effect on endothelial dysfunction

Sci China Life Sci. 2020 Mar;63(3):388-400. doi: 10.1007/s11427-018-9535-9. Epub 2019 Jun 12.

Abstract

The pathophysiology of preeclampsia (PE) remains unclear. PE spiral artery remodeling dysfunction and PE offspring cardiovascular future development has been a worldwide concern. We collected placental and umbilical artery samples from nor-motensive and PE pregnancies. Mineralocorticoid receptor (MR) and its alternative splicing variant (ASV) expression and their biological effects on PE were examined. An MR ASV was found to be highly expressed in all PE samples and slightly expressed in about half of the normotensive samples (umbilical artery, ~57.58%; placenta, ~36.84%). The MR ASV expression was positively associated with blood pressure in both groups. The MR ASV protein changed the aldosterone-induced expression pattern of MR target genes related to ion exchanges and cell signaling pathways. The MR ASV can also impair the proliferation, migration, and tube formation ability of endothelial cells. These findings indicate that MR ASV in PE placenta plays a pathogenic role in PE pathophysiology, especially in endothelial dysfunction, and the existence of the MR ASV in PE umbilical artery provides a new direction in the study of PE offspring with increased risk of cardiovascular diseases.

Keywords: alternative splicing variant; endothelial dysfunction; mineralocorticoid receptor; offspring; preeclampsia.

MeSH terms

  • Adult
  • Aldosterone / metabolism
  • Alternative Splicing / genetics*
  • Blood Pressure
  • DNA, Complementary / metabolism
  • Endothelial Cells / metabolism
  • Female
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Placenta / metabolism
  • Placenta Growth Factor
  • Pre-Eclampsia / drug therapy*
  • Pregnancy
  • Pregnancy Proteins
  • RNA / metabolism
  • Receptors, Mineralocorticoid / genetics
  • Receptors, Mineralocorticoid / metabolism*
  • Risk Factors
  • Vascular Diseases / drug therapy*
  • Vascular Diseases / metabolism

Substances

  • DNA, Complementary
  • Pregnancy Proteins
  • Receptors, Mineralocorticoid
  • Placenta Growth Factor
  • Aldosterone
  • RNA